{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:35Z","timestamp":1792801715650,"version":"4.5.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:p>Multiple myeloma (MM) is an incurable hematological malignancy with significant clinical and biological heterogeneity. Despite development and refinement of numerous prognostic models for MM, challenges with accurate and reliable risk stratification remain, highlighted by unexpected, early relapse or progression of disease in patients termed functional high-risk (FHR). To improve decision-making and optimise outcome, there is an unmet need for precise identification of high-risk (HR) patients, to enable tailored therapeutic strategies. With a complex and rapidly evolving treatment landscape, artificial intelligence (AI) and digital twin (DT) technology have emerged as potential tools for personalized medicine in MM. Through the integration and analysis of large data generated in clinical trials, registries and real-world cohorts, AI can inform therapy selection by creating advanced predictive models. DT, virtual patient-specific disease replicas, act as a dynamic, bidirectional bridge between real-world clinical data and computational simulations. Continuous acquisition of patient data, synchronized with DTs through AI-driven architectures, facilitates iterative risk recalibration. This ensures the virtual models accurately reflect evolving disease biology and treatment response. This review provides an overview of current and emerging risk stratification in MM, including genomic-based definitions of HR disease and the concept of FHR MM. We described the role, limitations and controversies of AI and DT in refining risk assessment, their predictive capacity for outcomes and therapy selection. Finally, we provide perspectives on the future of AI application in MM.<\/jats:p>","DOI":"10.3389\/fdgth.2026.1771531","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:57:15Z","timestamp":1773817035000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic"],"prefix":"10.3389","volume":"8","author":[{"given":"Cindy H.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network","place":["Adelaide, SA, Australia"]},{"name":"Faculty of Health and Medical Sciences, Adelaide University","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, Adelaide University","place":["Adelaide, SA, Australia"]},{"name":"Department of Genetics and Molecular Pathology, SA Pathology","place":["Adelaide, SA, Australia"]},{"name":"School of Pharmacy and Biomedical Science, College of Health, Adelaide University","place":["Adelaide, SA, Australia"]},{"name":"Centre for Cancer Biology, an alliance between SA Pathology and Adelaide University","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"McClure","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Science, College of Health, Adelaide University","place":["Adelaide, SA, Australia"]},{"name":"Centre for Cancer Biology, an alliance between SA Pathology and Adelaide University","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network","place":["Adelaide, SA, Australia"]},{"name":"Faculty of Health and Medical Sciences, Adelaide University","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish S.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, SA Pathology","place":["Adelaide, SA, Australia"]},{"name":"School of Pharmacy and Biomedical Science, College of Health, Adelaide University","place":["Adelaide, SA, Australia"]},{"name":"Centre for Cancer Biology, an alliance between SA Pathology and Adelaide University","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Hoow","family":"Kok","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, Adelaide University","place":["Adelaide, SA, Australia"]},{"name":"Department of Genetics and Molecular Pathology, SA Pathology","place":["Adelaide, SA, Australia"]},{"name":"School of Pharmacy and Biomedical Science, College of Health, Adelaide University","place":["Adelaide, SA, Australia"]},{"name":"Centre for Cancer Biology, an alliance between SA Pathology and Adelaide University","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/diagnostics15131708","article-title":"Challenges, difficulties, and delayed diagnosis of multiple myeloma","volume":"15","author":"Zorlu","year":"2025","journal-title":"Diagnostics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1038\/s41375-025-02654-y","article-title":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders","volume":"39","author":"Zanwar","year":"2025","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/10428194.2020.1849681","article-title":"Interdisciplinary approach to multiple myeloma \u2013 time to diagnosis and warning signs","volume":"62","author":"Herget","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/cncr.34778","article-title":"Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma","volume":"129","author":"Bumma","year":"2023","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e433520","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.16915","article-title":"Machine learning and artificial intelligence in haematology","volume":"192","author":"Shouval","year":"2021","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/s41591-021-01558-5","article-title":"Digital twins for predictive oncology will be a paradigm shift for precision cancer care","volume":"27","author":"Hernandez-Boussard","year":"2021","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3%3C842::AID-CNCR2820360303%3E3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International myeloma society\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1078-0432.CCR-21-3430","article-title":"A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma","volume":"28","author":"Guerrero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1186\/s12885-024-13124-6","article-title":"Clinical and immunological characteristics of high-risk double-hit multiple myeloma","volume":"24","author":"Shang","year":"2024","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.clml.2017.06.020","article-title":"Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma","volume":"17","author":"van Beers","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy JD","year":"2006","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/1878-0261.13055","article-title":"Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma","volume":"16","author":"Ebert","year":"2022","journal-title":"Mol Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s41375-020-0742-z","article-title":"Multiple myeloma DREAM challenge reveals epigenetic regulator PHF19 as marker of aggressive disease","volume":"34","author":"Mason","year":"2020","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/j.clml.2025.01.010","article-title":"Minimal residual disease testing infrastructure in multiple myeloma: guidance for clinical trial and routine practice use in Canada","volume":"25","author":"Mian","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/COC.0000000000001197","article-title":"Advancing MRD detection in multiple myeloma: technologies, applications, and future perspectives","volume":"48","author":"Chen","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.3390\/jcm9113519","article-title":"Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients","volume":"9","author":"Zamagni","year":"2020","journal-title":"J Clin Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41408-025-01327-4","article-title":"Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma","volume":"15","author":"Messiou","year":"2025","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"830922","DOI":"10.3389\/fonc.2022.830922","article-title":"Risk stratification before and during treatment in newly diagnosed multiple myeloma: from clinical trials to the real-world setting","volume":"12","author":"Bonello","year":"2022","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/hematology.2023000443","article-title":"A rational approach to functional high-risk myeloma","volume":"2023","author":"Gay","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/ajh.70070","article-title":"European Myeloma network consensus statement on functional high-risk multiple myeloma","volume":"100","author":"Lim","year":"2025","journal-title":"Am J Hematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1182\/blood-2023-177896","article-title":"Ultra high-risk multiple myeloma patients with multi-hit tumours and SKY92 high risk signature are at increased risk of early relapse even when treated with extended intensified induction and consolidation - results from the Optimum\/muknine trial","volume":"142","author":"Kaiser","year":"2023","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s44398-025-00009-2","article-title":"MyeVAE: a multi-modal variational autoencoder for risk profiling of newly diagnosed multiple myeloma","volume":"1","author":"Chang","year":"2025","journal-title":"BMC Artif Intell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.dajour.2023.100230","article-title":"A systematic review of explainable artificial intelligence models and applications: recent developments and future trends","volume":"7","author":"Saranya","year":"2023","journal-title":"Decis Anal J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030606","article-title":"Machine learning and deep learning applications in multiple myeloma diagnosis, prognosis, and treatment selection","volume":"14","author":"Allegra","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1158\/1078-0432.CCR-24-3475","article-title":"Modeling MRD changes in myeloma to understand treatment effects, predict outcomes, and investigate curative potential","volume":"31","author":"Gregory","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e70228","DOI":"10.1002\/hem3.70228","article-title":"Machine learning risk stratification strategy for multiple myeloma: insights from the EMN-HARMONY alliance platform","volume":"9","author":"Orgueira A","year":"2025","journal-title":"Hemasphere"},{"key":"B43","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41416-025-02987-6","article-title":"Individualized dynamic risk assessment and treatment selection for multiple myeloma","volume":"132","author":"Murie","year":"2025","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41746-024-01189-3","article-title":"Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma","volume":"7","author":"Hussain","year":"2024","journal-title":"NPJ Digit Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41698-023-00385-w","article-title":"ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma","volume":"7","author":"Park","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e760","DOI":"10.1097\/HS9.0000000000000760","article-title":"Prognostic stratification of multiple myeloma using clinicogenomic models: validation and performance analysis of the IAC-50 model","volume":"6","author":"Mosquera Orgueira","year":"2022","journal-title":"Hemasphere"},{"key":"B47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-022-00647-z","article-title":"Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish myeloma group","volume":"12","author":"Mosquera Orgueira","year":"2022","journal-title":"Blood Cancer J"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41375-021-01286-2","article-title":"Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data","volume":"35","author":"Mosquera Orgueira","year":"2021","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41746-025-01636-9","article-title":"Predicting progression events in multiple myeloma from routine blood work","volume":"8","author":"Ferle","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/bjh.20136","article-title":"Can we identify individuals at risk to develop multiple myeloma? A machine learning-based predictive model","volume":"207","author":"Mittelman","year":"2025","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic Index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100014","DOI":"10.1016\/j.bneo.2024.100014","article-title":"CD302 Predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib","volume":"1","author":"Kok","year":"2024","journal-title":"Blood Neoplasia"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/bloodadvances.2024015238","article-title":"Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations","volume":"9","author":"Shah","year":"2025","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/bloodadvances.2019000195","article-title":"Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib","volume":"3","author":"Kok","year":"2019","journal-title":"Blood Adv"},{"key":"B56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.17161","article-title":"CKLF And IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia","volume":"193","author":"Fitter","year":"2021","journal-title":"Br J Haematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3601","article-title":"Emerging artificial intelligence technologies for risk assessment and management in acute myeloid leukemia: a review","author":"Ansarian","year":"2025","journal-title":"JAMA Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"B59","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164019","article-title":"A personalized risk model for azacitidine outcome in myelodysplastic syndrome and other myeloid neoplasms identified by machine learning model utilizing real-world data","volume":"15","author":"Sharplin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1182\/bloodadvances.2022009173","article-title":"Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes","volume":"7","author":"Montarello","year":"2023","journal-title":"Blood Adv"},{"key":"B62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-021-00576-3","article-title":"Genomic characterization of functional high-risk multiple myeloma patients","volume":"12","author":"Soekojo","year":"2022","journal-title":"Blood Cancer J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1182\/blood.2025029987","article-title":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling","volume":"146","author":"Beer","year":"2025","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"83.e81","DOI":"10.1016\/j.jtct.2021.10.022","article-title":"Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41540-024-00345-5","article-title":"Forum on immune digital twins: a meeting report","volume":"10","author":"Laubenbacher","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"B67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41746-024-01073-0","article-title":"Digital twins for health: a scoping review","volume":"7","author":"Katsoulakis","year":"2024","journal-title":"NPJ Digit Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41746-025-01874-x","article-title":"Digital twins and big AI: the future of truly individualised healthcare","volume":"8","author":"Coveney","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s43588-024-00607-6","article-title":"Digital twins in medicine","volume":"4","author":"Laubenbacher","year":"2024","journal-title":"Nat Comput Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1349595","DOI":"10.3389\/fdgth.2024.1349595","article-title":"Toward mechanistic medical digital twins: some use cases in immunology","volume":"6","author":"Laubenbacher","year":"2024","journal-title":"Front Digit Health"},{"key":"B71","doi-asserted-by":"publisher","first-page":"100864","DOI":"10.1016\/j.landig.2025.02.004","article-title":"Medical digital twins: enabling precision medicine and medical artificial intelligence","volume":"7","author":"Sad\u00e9e","year":"2025","journal-title":"Lancet Digit Health"},{"key":"B72","doi-asserted-by":"publisher","first-page":"pgae456","DOI":"10.1093\/pnasnexus\/pgae456","article-title":"Complexity data science: a spin-off from digital twins","volume":"3","author":"Emmert-Streib","year":"2024","journal-title":"PNAS Nexus"},{"key":"B73","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41569-021-00630-4","article-title":"The health digital twin: advancing precision cardiovascular medicine","volume":"18","author":"Coorey","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12967-025-06371-z","article-title":"From virtual to reality: innovative practices of digital twins in tumor therapy","volume":"23","author":"Shen","year":"2025","journal-title":"J Transl Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41568-025-00850-7","article-title":"Application of digital twins for personalized oncology","volume":"25","author":"Asghar","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41585-025-01096-6","article-title":"Digital twins for personalized treatment in uro-oncology in the era of artificial intelligence","volume":"23","author":"G\u00f6rtz","year":"2026","journal-title":"Nat Rev Urol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41746-024-01188-4","article-title":"From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling","volume":"7","author":"Wang","year":"2024","journal-title":"NPJ Digit Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41746-025-01810-z","article-title":"Large language models-enabled digital twins for precision medicine in rare gynecological tumors","volume":"8","author":"Lammert","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e490","DOI":"10.1016\/S2352-3026(25)00170-X","article-title":"Virtual twins for personalised CAR T-cell therapy in myeloma","volume":"12","author":"Reiche","year":"2025","journal-title":"Lancet Haematol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41746-025-01809-6","article-title":"Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies","volume":"8","author":"Weirauch","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/2159-8290.CD-23-1500","article-title":"The virtual child","volume":"14","author":"Gilbertson","year":"2024","journal-title":"Cancer Discov"},{"key":"B82","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cmet.2025.10.022","article-title":"Digital twins for in vivo metabolic flux estimations in patients with brain cancer","volume":"38","author":"Meghdadi","year":"2026","journal-title":"Cell Metab"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1324453","DOI":"10.3389\/fdgth.2023.1324453","article-title":"A digital twin model for evidence-based clinical decision support in multiple myeloma treatment","volume":"5","author":"Grieb","year":"2023","journal-title":"Front Digit Health"},{"key":"B84","doi-asserted-by":"publisher","first-page":"bbaf237","DOI":"10.1093\/bib\/bbaf237","article-title":"Advances and critical aspects in cancer treatment development using digital twins","volume":"26","author":"Bouriga","year":"2025","journal-title":"Brief Bioinform"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.3390\/cancers16223817","article-title":"Advancing precision oncology with digital and virtual twins: a scoping review","volume":"16","author":"\u0218tef\u0103nig\u0103","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e000893","DOI":"10.1136\/bmjonc-2025-000893","article-title":"Digital twins in oncology: where we are and where we hope to go","volume":"4","author":"McCoy","year":"2025","journal-title":"BMJ Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1007784","DOI":"10.3389\/fdgth.2022.1007784","article-title":"Exploring approaches for predictive cancer patient digital twins: opportunities for collaboration and innovation","volume":"4","author":"Stahlberg","year":"2022","journal-title":"Front Digit Health"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1421591","DOI":"10.3389\/fphys.2024.1421591","article-title":"Patient-specific prostate tumour growth simulation: a first step towards the digital twin","volume":"15","author":"P\u00e9rez-Benito","year":"2024","journal-title":"Front Physiol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1260361","DOI":"10.3389\/frai.2023.1260361","article-title":"Understanding the need for digital twins\u2019 data in patient advocacy and forecasting oncology","volume":"6","author":"Chang","year":"2023","journal-title":"Front Artif Intell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1624877","DOI":"10.3389\/frai.2025.1624877","article-title":"From data-driven cities to data-driven tumors: dynamic digital twins for adaptive oncology","volume":"8","author":"Karaman","year":"2025","journal-title":"Front Artif Intell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.38124\/ijisrt\/25oct1106","article-title":"Application of artificial intelligence in predicting survival outcomes in multiple myeloma cancer patients: a systematic review","volume":"10","author":"Oyetoro","year":"2025","journal-title":"Int J Innov Sci Res Technol"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1771531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:57:16Z","timestamp":1773817036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1771531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":91,"alternative-id":["10.3389\/fdgth.2026.1771531"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2026.1771531","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1771531"}}